These fast-growing companies have new personnel announcements to share. Photos courtesy

Three Houston startups have new hires they're excited about. From new board members to C-level execs, here's who's moving and shaking in Houston innovation.

Software company hires new product exec

Photo courtesy of Cart.com

Cart.com, an end-to-end e-commerce services provider, announced Michael Svatek as the company's first chief product officer. Formerly, Svatek served as chief product and strategy officer at Bazaarvoice and then co-founded and served as the CEO and head of product at Rivet Works, a cloud software platform.

"Michael's deep expertise across the e-commerce technology value chain coupled with his experience in M&A, strategic alliances, and entrepreneurship are one-of-a-kind in this industry, and a testament to our growth and trajectory at Cart.com," says Omair Tariq, Cart.com co-founder and CEO, in a news release. "We are so pleased to welcome Michael, a proven leader with an innate understanding of the Cart.com mission to unify and streamline the fragmented e-commerce value chain for brands of any size."

Earlier this year, Cart.com raised a $25 million series A funding round and emerged from stealth mode.

Fast-growing e-commerce startup lawyers up

Photo courtesy of GoExpedi

Houston-based GoExpedi, another tech company disrupting e-commerce, once again expanded its executive board, naming Julie Gremillion as general counsel. She has more than 10 years of experience in working with energy companies, and will lead the company's legal strategy, managing compliance and risk throughout the organization, and more.

"We are thrilled to have found Julie, one of the most experienced, savvy and well-rounded legal counsels in the industry," says Tim Neal, GoExpedi CEO, in a news release. "Her legal background in the energy space is beyond reproach. As we enter this next critical phase of growth, Julie's combined commercial and legal expertise will provide us with a platform for long-term and sustainable success."

GoExpedi also recently fundraised a $25 million round last fall.

Recently acquired therapeutics company adds board member

Photo via aiche.org

Clinical-stage biotechnology company, Coya Therapeutics Inc. has appointed Ann Lee., senior vice president of Cell Therapy Development and Operations at Bristol Myers Squibb, to the company's board of directors.

"Dr. Lee is one of the leading cell therapy technical development, supply chain and manufacturing executives in the biopharmaceutical industry," says Howard Berman, Coya CEO, says in a release. "At Coya, we are revolutionizing cell therapy manufacturing and supply chain management via proprietary cryopreservation to overcome prior limitations of Treg cell therapies. Dr. Lee's expertise will be instrumental as we advance in the clinic and build out manufacturing partnerships."

The company, which focuses on creating therapeutics for neurodegenerative and autoimmune diseases, announced earlier this year that it has completed a merger with Nicoya Health Inc. and raised $10 million in its series A.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.